The NextGen Bio Class of 2019 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future. Congratulations to this group!
Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Chemotherapy (CT) has been used in the treatment of cancer since the late 1940s. A new class of chemotherapeutic agents called taxanes were introduced in the 1990s and remains on of the key advances in the fight against cancer.
Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although there has been an explosion in immunotherapy development, small molecules continue to dominate the treatment of cancers, and recent research reveals that chemotherapies, such as taxanes, benefit immunotherapies.
NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting
FT. WORTH/DALLAS, (May 16, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company, will present data from preclinical studies of inhaled NanoPac (submicron particle paclitaxel) showing prolonged retention of drug in lung tissue and significant tumor regression without adverse drug-related observations in an orthotopic animal model of non-small cell lung cancer (NSCLC).
New Cancer Answer
FORT WORTH, Texas—Researchers have been trying to develop therapeutic agents powerful enough to destroy tumors without harmful effects to healthy cells for a long time. NanOlogy is working toward this goal by trying to transform systemic chemotherapy into local delivery of naked nanoparticles to treat various forms of cancer with greater efficacy and safety.
NanOlogy takes nanoparticle tech into Phase II trials
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer.
DFB Pharmaceuticals, CritiTech, and US Biotest Form NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
Systemic chemotherapy transformed into local delivery with potential for greater efficacy and safety to treat cancer and other serious illnesses
FORT WORTH, Texas, Sep 12, 2017 (BUSINESS WIRE) — DFB Pharmaceuticals, a private investment and development group, in collaboration with CritiTech and US Biotest, has formed NanOlogy to finance and develop a breakthrough technology platform to produce unique, patented, naked nanoparticle forms of paclitaxel and docetaxel for local delivery with the potential for greater efficacy and safety to treat cancer and other serious illnesses.